Treatment for Airflow Obstruction, Chronic

1
Effectiveness
1
Safety
Virginia Commonwealth University, Richmond, VA
Airflow Obstruction, Chronic+3 More
Eligibility
18+
All Sexes
Eligible conditions
Airflow Obstruction, Chronic

Study Summary

This study is evaluating whether resveratrol may have positive impacts for individuals with chronic obstructive pulmonary disease.

See full description

Eligible Conditions

  • Airflow Obstruction, Chronic
  • Pulmonary Disease, Chronic Obstructive
  • Lung Diseases, Obstructive
  • Lung Diseases
  • Chronic Obstructive Pulmonary Disease (COPD)

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 3 primary outcomes and 2 secondary outcomes in patients with Airflow Obstruction, Chronic. Measurement will happen over the course of Baseline to 12 weeks.

Baseline to 12 weeks
Change in Inflammatory activation
Change in Nitric Oxide metabolism
Change in Sirt1 concentrations
Change in Systemic Inflammation
Change in vascular health

Trial Safety

Safety Estimate

1 of 3

Trial Design

2 Treatment Groups

Resveratrol
Placebo group

This trial requires 48 total participants across 2 different treatment groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.

Resveratrol
DietarySupplement
500 mg of time released micronized trans-Resveratrol
Placebo
Other
Placebo will be used in the form of an empty white colored soft vegetarian capsule as resveratrol is presented

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 12 weeks
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly baseline to 12 weeks for reporting.

Closest Location

Virginia Commonwealth University - Richmond, VA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
in the study People who have COPD and have known about it for at least a year are allowed to participate in the study. show original
predicted A person with a FEV1 of less than 80% of the predicted value after bronchodilator and a TLC of more than 80% of the predicted value would likely be considered to have chronic obstructive pulmonary disease (COPD). show original
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages are II to IV show original
Healthy volunteers without COPD were matched. show original
A breathing test ratio (FEV1/FVC) of less than 0.7 indicates a person has a restrictive lung disease. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have there been other clinical trials involving treatment?

Add answer

The majority of current clinical trials are not designed to investigate treatment effects. Inclusion criteria, design characteristics, statistical analyses were all poorly reported most commonly leading to biased interpretations of trial results. Further, only a small minority of randomized controlled trials reported statistical significance in meta-analyses, which do not necessarily provide unbiased estimates of treatment effects.

Unverified Answer

What are the signs of airflow obstruction, chronic?

Add answer

Signs of airway obstruction can be found at the back of the neck, [not only in patients with respiratory infection (bronchitis)] but also in patients without (asthma and COPD).[Power(http://www.withpower.com/clinical-trials/respiratory-diseases-and-pneumoconiosis).

Unverified Answer

What are common treatments for airflow obstruction, chronic?

Add answer

There are multiple treatment options for airflow obstruction, chronic, which may include lifestyle changes such as diet, smoking cessation, and exercise, and medications such as inhaled corticosteroids, theophylline, steroids, and leukotriene receptor antagonists.

Unverified Answer

What is airflow obstruction, chronic?

Add answer

Although both the prevalence and disease severity of airflow obstruction, chronic were high in this adult population, airflow obstruction, chronic was more prevalent among women than among men. Smoking was significantly associated with airflow obstruction, chronic only in women. It is not uncommon for patients with airflow obstruction, chronic, to require an examination of their pulmonary function. Although airflow obstruction, chronic is marked by chronic airflow obstruction, this condition should be evaluated in the context of other diseases that may be causing the obstruction.

Unverified Answer

Can airflow obstruction, chronic be cured?

Add answer

Although AOA is associated with increased mortality, and it is currently recommended that all persons with airflow obstruction cease smoking, this does not appear to be the case. Even after AOA is diagnosed, a substantial percentage of all people are quitting smoking.

Unverified Answer

What causes airflow obstruction, chronic?

Add answer

Chronic airflow obstruction arises mainly from smoking, with a lesser role of exposure to dust, pesticides, or other chemicals. In non-smokers, chronic airflow obstruction is probably multifactorial. Chronic airflow obstruction is more common in women than men. It is most prevalent in the elderly, with a sharp rise in incidence between the sixth and seventies, and is most frequent in whites in North America. We also found a high prevalence of chronic airflow obstruction in the general population of the city of Puerto Rico, and the highest prevalence in persons in the 50-69 age group.

Unverified Answer

How many people get airflow obstruction, chronic a year in the United States?

Add answer

Chronic airflow obstruction occurs in more than 1.1 million US adults a year. The leading cause of airflow obstruction was airway obstruction in the presence of other causes.

Unverified Answer

Does airflow obstruction, chronic run in families?

Add answer

Positive control family members can have a more significant impact on the prevalence of airflow obstruction than negative control relatives among Ashkenazi Jewish families. The strong effect on the disease-affected parent with and without history of airflow obstruction suggests the presence of factors that may cause a vulnerability to airflow obstruction among the parents. These data support the utility of a positive control pedigree with known airflow obstruction and a negative control pedigree to identify risk factors in ASIAO families.

Unverified Answer

What is the average age someone gets airflow obstruction, chronic?

Add answer

airway obstruction, chronic, is more common and present earlier in life in Finland [Finlander] than reported earlier in literature. In Finland the age-adjusted age in relation to time period is earlier than reported from other industrialized countries.

Unverified Answer

Is treatment safe for people?

Add answer

It is hard to determine whether the harms of treatment outweigh the risks of waiting. People should be questioned on this topic before considering participation in clinical trials.

Unverified Answer

Who should consider clinical trials for airflow obstruction, chronic?

Add answer

Most patients with airflow obstruction, chronic were not considered for clinical trials. Many patients would be eligible for clinical trials if they were asked what they thought their clinical circumstances would be like should they not be receiving medical treatment. In contrast to other respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease [COPD]), the majority of patients with airflow obstruction, chronic are not currently considering clinical trials. Most do not perceive themselves to have an increased likelihood of being enrolled as a result, nor do they have any intention to participate in clinical trials. Given that a large number of patients with airflow obstruction, chronic would be eligible for clinical trials, the number who could be enrolled must be increased.

Unverified Answer

What is treatment?

Add answer

A number of surgical, nonsurgical, and nonoperable interventions have been found to be effective in management of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer). It is important to evaluate the most effective therapeutic paradigm for patients with advanced pulmonary malignancies and to use it with caution to avoid unnecessary and harmful interventions. In particular, we provide a detailed description of the current paradigms for metastatic disease, adjuvant treatment for resected patients, and treatment to alleviate breathlessness in advanced cancer patients.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Airflow Obstruction, Chronic by sharing your contact details with the study coordinator.